IGC vs IMA

IGC Pharma, Inc. vs ImageneBio, Inc. — Valuation Comparison 2026

IGC

Biotechnology
IGC Pharma, Inc.
Quality
5.4
out of 10
Value Trap
38
LOW
Price
$0.29
Last close
Models
11/13
Active
VS

IMA

Biotechnology
ImageneBio, Inc.
Quality
5.8
out of 10
Value Trap
35
LOW
Price
$5.92
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType IGC Fair ValueIGC Upside IMA Fair ValueIMA Upside
Bayesian DCF Intrinsic $0.08 -73.3% $6.30 +11.4%
Earnings Power Value Intrinsic $0.09 -72.7% $8.75 +54.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IGC vs IMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IGC vs IMA — Which Stock Is More Undervalued?

IMA scores higher with a 5.8/10 quality rating vs IGC's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IGC Pharma, Inc. (IGC) and ImageneBio, Inc. (IMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IGC currently trades at $0.29 with a QOC of 5.4/10, while IMA trades at $5.92 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).